Diagnosis and surgical treatment for stage I non-small-cell lung cancer.
- Author:
Yu-Shun GAO
1
;
De-Chao ZHANG
;
Jie HE
;
Ke-Lin SUN
;
Da-Wei ZHANG
;
Ru-Gang ZHANG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; diagnosis; pathology; surgery; Female; Follow-Up Studies; Humans; Lung Neoplasms; diagnosis; pathology; surgery; Lymph Node Excision; Male; Mediastinum; Middle Aged; Neoplasm Staging; Pneumonectomy; methods; Survival Rate
- From: Chinese Journal of Oncology 2005;27(1):52-55
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the results of surgery and the diagnosis of stage I non-small-cell lung cancer (NSCLC).
METHODSThe survival of 274 stage I NSCLC patients who underwent surgery from 1991 to 1998 were statistically analyzed by the Kaplan-Meier method. Comparison of the differences in survival rates among groups were made according to the Logrank test. The follow-up time was at least 5 years with a follow-up rate of 97.8%.
RESULTSThe overall 1-, 3-, 5-year survival rates for patients with pathologic stage I lesion were 92.9%, 79.6% and 66.1%. The 5-year survival rates for patients with squamous-cell carcinoma, adenocarcinoma, adenosquamous and alveolar-cell carcinoma were 73.3%, 55.3%, 52.2%, 71.7%, respectively. The 1-, 3-, 5-year survival rates for T1N0 were 95.0%, 83.2%, 74.3% whereas those of T2N0 lung lesions were 90.8%, 75.9%, 59.9% (P < 0.05). The 1-, 3-, 5-year survival rates of regular lobectomy were 94.1%, 79.3%, 67.5% and of conservative resection (segmentectomy and wedge resection) were 76.5%, 50.0%, 38.3% (P < 0.05). There was no perioperative mortality. The postoperative complications were: intrathoracic hemorrhage (2 patients, successfully treated by second thoracotomy) and chylothorax (1 patient, healed after conservative treatment).
CONCLUSIONThe 5-year survival rate of pathologic stage I non-small-cell lung cancer is 66.1%. The outcome of patients with squamous-cell carcinoma (73.3%) is similar to that of alveolar-cell carcinoma (71.7%) which, however, is better than that of adenocarcinoma (55.3%) or adenosquamouscarcinoma (52.5%). The overwhelming superiority in result of IA (T1N0) lesion (74.3%) over the IB (T2N0) disease (59.9%) is quite impressive. Regular lobectomy plus radical mediastinal lymph node dissection is the appropriate management for stage I non-small-cell lung cancer.